Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25118180 | 0.91 | HRH2 (0.38) | HTTKDM4EALDH1A1GBA1GNAI3 | |
| SCHEMBL22963141 | 0.89 | KDM4E (0.37) | HTTKDM4EALDH1A1GBA1TP53 | |
| SCHEMBL20850751 | 0.89 | KDM4E (0.37) | HTTKDM4EALDH1A1GBA1TP53 | |
| SCHEMBL22169658 | 0.89 | HTT (0.35) | HTTKDM4EALDH1A1GNAI3GNAO1 | |
| SCHEMBL24673304 | 0.86 | HRH3 (0.35) | HTTGBA1GNAI3GNAO1GNAI1 | |
| SCHEMBL22963144 | 0.84 | GBA1 (0.38) | HTTKDM4EALDH1A1GBA1TP53 | |
| SCHEMBL25518503 | 0.83 | USP2 (0.33) | HTTKDM4EALDH1A1GBA1GNAI3 | |
| SCHEMBL21449107 | 0.83 | GNAI3 (0.44) | HTTKDM4EALDH1A1GNAI3GNAO1 | |
| SCHEMBL22848922 | 0.82 | MAPK1 (0.39) | HTTKDM4EALDH1A1GBA1TP53 | |
| SCHEMBL24847753 | 0.82 | ALDH1A1 (0.45) | HTTKDM4EALDH1A1GBA1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | SHENZHEN UNIVERSITY (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | IFNG, IFNAR1, STING1 | HTT 4539/4885KDM4E 4615/4885ALDH1A1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.